Malte Peters will leave Sandoz to take over as Chief Development Officer of Morphosys AG. Peters succeeds Arndt Schottelius, who held the position for eight yeara.
Novozymes company Albumedix A/S has appointed Giles Campion new Chief Medical Officer. Campion will be in charge of leading the development efforts of the Danish leader in albumin-based drug delivery.
Milan-based Newron Pharmaceuticals has named Dennis Dionne Vice President Commercial Affairs. Previously, Dionne was Executive Director for Commercial Operations. He replaces Anders Haegerstrand.
Deborah Waterhouse, currently Senior Vice President Primary Care, GSK US Pharmaceuticals, will take over as CEO of Viiv Healthcare. She succeeds Dominique Limet, who will step down from the post at the end of March 2017.
Co-founder of immuno-oncology start-up Innate Pharma Hervé Brailly is making room on the chair of the executive board. His successor Mondher Majhoubi transfers from AstraZeneca, where he was Senior Vice President, Therapeutic Area Head-Oncology, Global Product and Portfolio Strategy.
Gene therapy company uniQure NV has named Matthew Kapusta its new Chief Executive Officer. Kapusta has been interim CEO since September and also served as Chief Financial Officer for the last two years.
Among other appointments, BASF has named Melanie Maas-Brunner as new President Nutrition and Health, effective April 1, 2017. Previously, Maas-Brunner held the position of Senior Vice President Performance Materials Europe.
Drug discovery company Confo Therapeutics has appointed John Edward Berriman as non-executive director and chairman of the board of directors. Berriman is set to take his seat on the board December 21.
Antifungal drug developer F2G Ltd has appointed distinguished research scientist John Rex to the position of Chief Medical Officer.
At the beginning of October, Isabel De Paoli assumed the position of Chief Strategy Officer at German healthcare company Merck GmbH. She will head the Group Strategy and Transformation Function, which has just been created.